000181263 001__ 181263
000181263 005__ 20240229145644.0
000181263 0247_ $$2doi$$a10.1093/jnci/djac151
000181263 0247_ $$2pmid$$apmid:35980168
000181263 0247_ $$2ISSN$$a0027-8874
000181263 0247_ $$2ISSN$$a0198-0157
000181263 0247_ $$2ISSN$$a1460-2105
000181263 0247_ $$2altmetric$$aaltmetric:134757882
000181263 037__ $$aDKFZ-2022-01906
000181263 041__ $$aEnglish
000181263 082__ $$a610
000181263 1001_ $$aKratz, Christian P$$b0
000181263 245__ $$aHeterozygous BRCA1/2 and Mismatch Repair Gene Pathogenic Variants in Children and Adolescents with Cancer.
000181263 260__ $$aOxford$$bOxford Univ. Press$$c2022
000181263 3367_ $$2DRIVER$$aarticle
000181263 3367_ $$2DataCite$$aOutput Types/Journal article
000181263 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1669122678_16030
000181263 3367_ $$2BibTeX$$aARTICLE
000181263 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000181263 3367_ $$00$$2EndNote$$aJournal Article
000181263 500__ $$a2022 Nov 14;114(11):1523-1532
000181263 520__ $$aGenetic predisposition is a significant cause of cancer, yet little is known about the role of 'adult cancer predisposition syndromes' in childhood cancer. We examined the extent to which heterozygous pathogenic germline variants in BRCA1, BRCA2, PALB2, ATM, CHEK2, MSH2, MSH6, MLH1, and PMS2 contribute to cancer risk in children and adolescents.We conducted a meta-analysis of 11 studies that incorporated comprehensive germline testing for children and adolescents with cancer. ClinVar pathogenic/likely pathogenic variants (PVs) in genes of interest were compared to two control groups. Results were validated in a cohort of mainly European cases and controls. We employed the Proxy External Controls Association Test to account for different pipelines.Among 3,975 children/adolescents with cancer, significant associations with cancer risk were observed for PVs in BRCA1/2 (26 PVs vs 63 PVs among 27,501 controls, OR 2.78, 95%-CI 1.69-4.45, p<.001) and mismatch repair (MMR) genes (19 PVs vs 14 PVs among 27,501 controls, OR 7.33, 95%-CI 3.64-14.82, p<.001). Associations were seen in brain and other solid tumors, yet not in hematologic neoplasms. We confirmed similar findings in 1,664 pediatric cancer patients primarily of European descent.These data suggest that heterozygous PVs in BRCA1/2 and MMR genes contribute with reduced penetrance to cancer risk in children/adolescents. No changes to predictive genetic testing and surveillance recommendations are required.
000181263 536__ $$0G:(DE-HGF)POF4-312$$a312 - Funktionelle und strukturelle Genomforschung (POF4-312)$$cPOF4-312$$fPOF IV$$x0
000181263 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000181263 7001_ $$aSmirnov, Dmitrii$$b1
000181263 7001_ $$0P:(DE-He78)50c2928009c788a6a5f3a0708dfb6df5$$aAutry, Robert$$b2$$udkfz
000181263 7001_ $$0P:(DE-He78)bff9e3e3d86865d2b0836bb8f3ce98f3$$aJäger, Natalie$$b3$$udkfz
000181263 7001_ $$aWaszak, Sebastian M$$b4
000181263 7001_ $$aGroßhennig, Anika$$b5
000181263 7001_ $$aBerutti, Riccardo$$b6
000181263 7001_ $$aWendorff, Mareike$$b7
000181263 7001_ $$aHainaut, Pierre$$b8
000181263 7001_ $$0P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9$$aPfister, Stefan$$b9$$udkfz
000181263 7001_ $$aProkisch, Holger$$b10
000181263 7001_ $$aRipperger, Tim$$b11
000181263 7001_ $$aMalkin, David$$b12
000181263 773__ $$0PERI:(DE-600)1465951-7$$a10.1093/jnci/djac151$$gp. djac151$$n11$$p1523-1532$$tJournal of the National Cancer Institute$$v114$$x0027-8874$$y2022
000181263 909CO $$ooai:inrepo02.dkfz.de:181263$$pVDB
000181263 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)50c2928009c788a6a5f3a0708dfb6df5$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000181263 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)bff9e3e3d86865d2b0836bb8f3ce98f3$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000181263 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9$$aDeutsches Krebsforschungszentrum$$b9$$kDKFZ
000181263 9131_ $$0G:(DE-HGF)POF4-312$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunktionelle und strukturelle Genomforschung$$x0
000181263 9141_ $$y2022
000181263 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-01-28
000181263 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2021-01-28
000181263 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-01-28
000181263 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2022-11-18$$wger
000181263 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJNCI-J NATL CANCER I : 2021$$d2022-11-18
000181263 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-18
000181263 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-18
000181263 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2022-11-18
000181263 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2022-11-18
000181263 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-18
000181263 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-18
000181263 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2022-11-18
000181263 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2022-11-18
000181263 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2022-11-18
000181263 915__ $$0StatID:(DE-HGF)9910$$2StatID$$aIF >= 10$$bJNCI-J NATL CANCER I : 2021$$d2022-11-18
000181263 9201_ $$0I:(DE-He78)B062-20160331$$kB062$$lB062 Pädiatrische Neuroonkologie$$x0
000181263 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x1
000181263 980__ $$ajournal
000181263 980__ $$aVDB
000181263 980__ $$aI:(DE-He78)B062-20160331
000181263 980__ $$aI:(DE-He78)HD01-20160331
000181263 980__ $$aUNRESTRICTED